The trajectory of companies tied to iconic drugs like Viagra presents a complex investment picture. While the initial surge of copyright, fueled by Viagra's extraordinary popularity, generated substantial wealth , the loss of exclusivity in key regions has introduced substantial volatility. Investors are now grappling with the impact of generic com